ResMed | RMD - Selling And Administration Expenses

Stock Price
230.84
Daily Change
-1.57 -0.68%
Monthly
-9.76%
Yearly
2.98%
Q1 Forecast
223.87

ResMed reported $278.4M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Ansell USD 274.8M 7.6M Dec/2025
Artivion USD 50.02M 697K Sep/2024
AtriCure USD 78.34M 109K Dec/2025
Baxter International USD 761M 53M Dec/2025
Cochlear AUD 449.4M 214.45M Dec/2025
Cooper Companies USD 373.1M 46.1M Dec/2025
CSL USD 1.23B 498M Dec/2025
Dexcom USD 299.9M 31.5M Dec/2025
Edwards Lifesciences USD 602.9M 88.3M Dec/2025
Fisher Paykel Healthcare NZD 285.5M 11.6M Dec/2025
Globus Medical USD 318.48M 4.88M Dec/2025
Haemonetics USD 109.15M 7.54M Dec/2025
Hologic USD 2.5B 2.24B Dec/2025
Idexx Laboratories USD 275.68M 10.58M Dec/2025
Inogen USD 43.77M 510K Jun/2024
Insulet USD 331.4M 16.2M Dec/2025
Integra LifeSciences USD 156.45M 12.6M Dec/2025
Intuitive Surgical USD 687.1M 113.8M Dec/2025
Masimo USD 128M 11.6M Dec/2025
Medtronic 2.97B 159M Sep/2025
Philips EUR 1.31B 127M Dec/2025
Ramsay Health Care AUD 5.29B 3.2M Dec/2024
ResMed USD 278.4M 19.2M Dec/2025
Sigma Healthcare AUD 134.77M 9.73M Dec/2024
Sonic Healthcare AUD 2.52B 2.46B Dec/2024
Steris USD 352.3M 2.6M Dec/2025
Teleflex USD 222.37M 59.4M Dec/2025
Thermo Fisher Scientific USD 1.98B 182M Dec/2025